CD274 and non-small cell lung carcinoma: In light of these results, the National Medical Products Administration (NMPA) authorized the use of atezolizumab for adjuvant therapy in stage II–IIIA NSCLC patients with PD-L1 expression ≥1% following complete resection and platinum-based chemotherapy.